Replimune Group, Inc. (REPL)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

13.42 on 9 Oct 2026

0 buys14 sales at will3 planned sales

Fiscal year 2026, ended 31 Mar 2026, as filed

Net income

$313.94M

Free cash flow

$284.57M

Return on equity

-188.9%

Return on capital

-101.3%

Debt to equity

0.50

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
17 Aug 2026	Hill Emily Luisa Chief Financial Officer	Sold at will	$132.18K	4.1%
10 Aug 2026	Patel Sushil Chief Executive Officer	Sold at will	$510.25K	5.3%
10 Aug 2026	Hill Emily Luisa Chief Financial Officer	Sold at will	$148.48K	4.8%
10 Aug 2026	Xynos Konstantinos Chief Medical Officer	Sold at will	$148.47K	4.9%
10 Aug 2026	Schwendenman Andrew Chief Accounting Officer	Sold at will	$98.99K	7.1%
1 Jun 2026	Sarchi Christopher Chief Commercial Officer	Sold on a plan	$110.88K	6.2%

21out of 100

Profitability 0

Financial strength 64

Growth n/a

Insiders 0

Strongest on financial strength (64), weakest on insiders (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$1.93M

17 sales

Planned sales

18%

under a 10b5-1 plan